Frontier IP, a specialist in commercialising university intellectual property, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as the Group's sole broker with immediate effect.
Allenby Capital Limited remains the Group's Nominated Adviser.
Frontier IP Group Plc
T: 020 7332 2338
Neil Crabb, Chief Executive
Andrew Johnson, Communications & Investor Relations
M: 07464 546 025
Allenby Capital Limited (Nominated Adviser)
T: 0203 328 5656
Nick Athanas / Nicholas Chambers
N+1 Singer (Broker)
T: 0207 496 3000
Harry Gooden / George Tzimas
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Neil Crabb, chief executive of Frontier IP Group Plc (LON:FIPP) caught up with Proactive's Andrew Scott following the release of their half-year report.
Frontier’s portfolio includes AI drug researcher Exscientia which secured a €15mln strategic investment from drug discovery company...